Yakult Honsha has patented a method to predict the effectiveness of FOLFOX or FOLFIRI regimens for stage IV colorectal cancer treatment. By measuring copy number gains in specific chromosome regions, the method helps select the most advantageous regimen for individual patients. GlobalData’s report on Yakult Honsha gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Yakult Honsha Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Yakult Honsha, Cancer treatment biomarkers was a key innovation area identified from patents. Yakult Honsha's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Method to select folfox or folfiri regimen for colorectal cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Yakult Honsha Co Ltd

A recently granted patent (Publication Number: US11879150B2) outlines a selection method for determining the appropriate regimen, FOLFOX or FOLFIRI, for treating colorectal cancer based on specific genetic markers. The method involves measuring the copy number gain in various regions on human chromosomes in tumor tissue specimens. If the copy number gain is detected in certain regions like 7q34, 8q24.1, 8q24.2, among others, the FOLFIRI regimen is recommended. Conversely, if no gain is observed in the 9q34.3 region, the FOLFIRI regimen is also suggested. On the other hand, if a gain is detected in the 7p15.3 region but not in the 8q24.1 region, the FOLFOX regimen is recommended for treatment.

This patent provides a methodical approach to personalize treatment decisions for colorectal cancer patients by analyzing specific genetic markers. By identifying copy number gains in key regions on human chromosomes, healthcare providers can make informed choices between the FOLFOX and FOLFIRI regimens. This tailored approach aims to optimize treatment outcomes and enhance the efficacy of colorectal cancer therapy by aligning the regimen selection with the patient's genetic profile, potentially leading to more targeted and effective treatment strategies.

To know more about GlobalData’s detailed insights on Yakult Honsha, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.